Guidance for market authorization requirements for COVID-19 drugs: Communications and transparency
Information about drugs under review and those that are authorized are posted on the Government of Canada's website or provided upon request.
For example, our list of applications received includes COVID-19 drugs under review. Once authorized, COVID-19 drugs are included in our list of authorized drugs. A regulatory decision summary is published at the time of authorization. A summary basis of decision gives health care system partners and the public access to data and information supporting the authorization.
We include information on drug inspection outcomes and measures in the drug and health product inspections database. Detailed clinical data are provided under the Public Release of Clinical Information initiative, in accordance with Health Canada's guidance on the public release of clinical information.
Report a problem or mistake on this page
- Date modified: